FN2 Earnings Intelligence
United Therapeutics Corporation income statement (quarterly)
United Therapeutics Corporation (UTHR) Income Statement (quarterly) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - |
| - Cash | $1,899.9 | $1,593.1 | $1,340.1 | $1,279.7 | $1,803.2 |
| + Debt | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - |
| Revenue | $794.4 | $798.6 | $799.5 | $781.5 | $783.3 |
| % Growth | - | - | - | - | - |
| Gross Profit | $701.9 | $711 | $698.6 | $648.1 | $683.8 |
| % Margin | 88.4% | 89.0% | 87.4% | 82.9% | 87.3% |
| EBITDA | $402.6 | - | - | $348.4 | - |
| % Margin | 50.7% | - | - | 44.6% | - |
| Net Income | $322.2 | $309.5 | $338.7 | $274.9 | $333 |
| % Margin | 40.6% | 38.8% | 42.4% | 35.2% | 42.5% |
| Diluted EPS | $6.63 | $6.41 | $7.16 | $5.82 | $7.27 |
| % Growth | - | - | - | - | - |
| Operating Cash Flow | $461.2 | - | - | $463.3 | - |
| CapEx | $74.9 | - | - | $100.8 | - |
| Free Cash Flow | $386.3 | - | - | $362.5 | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Revenue | $794.4 | $798.6 | $799.5 | $781.5 | $783.3 |
| Gross Profit | $701.9 | $711 | $698.6 | $648.1 | $683.8 |
| EBITDA | $402.6 | - | - | $348.4 | - |
| Net Income | $322.2 | $309.5 | $338.7 | $274.9 | $333 |
| Diluted EPS | $6.63 | $6.41 | $7.16 | $5.82 | $7.27 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | $1,899.9 | $1,593.1 | $1,340.1 | $1,279.7 | $1,803.2 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | $200 | - | - | - | - |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | $461.2 | - | - | $463.3 | - |
| Capital Expenditure | $74.9 | - | - | $100.8 | - |
| Free Cash Flow | $386.3 | - | - | $362.5 | - |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - |
| Gross Margin | 88.4% | 89.0% | 87.4% | 82.9% | 87.3% |
| EBITDA Margin | 50.7% | - | - | 44.6% | - |
| Net Margin | 40.6% | 38.8% | 42.4% | 35.2% | 42.5% |
| FCF Margin | 48.6% | - | - | 46.4% | - |
| Diluted EPS Growth | - | - | - | - | - |
Get the UTHR recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.